Zacks Investment Research
10 Nov 2025, 13:50 UTC · 44w ago
Verdict
Headline takes no side. We score LLY −0.60 across four claims — strongly bearish.
−0.60strongly bearish
More negative than 82% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Eli Lilly and Novo Nordisk have agreed to slash prices for GLP-1 obesity drugs (Ozempic, Wegovy, Zepbound) to roughly $350 per month, down from list prices over $1,000.
More negative than 98% of claims this week
The Trump administration is implementing a 'Most-Favored-Nation' (MFN) drug pricing policy to force U.S. prices to match the lowest prices in other advanced countries, including mandates on all new products.
So whatBroad systemic pricing pressure across the pharmaceutical industry increases long-term margin risk for the entire sector.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 96% of claims this week
Medicare will now cover obesity drugs for the first time due to reduced pricing agreements.
More positive than 77% of claims this week
Eli Lilly and Novo Nordisk committed to new U.S. manufacturing investments totaling at least $37 billion ($27B from LLY and $10B from NVO).
More negative than 66% of claims this week
Which stocks this story touches
More negative than 82% of ticker scores this week
Company agreed to significantly slash prices of obesity drugs, posing a direct financial challenge to revenue and earnings.
More negative than 82% of ticker scores this week
Company agreed to significantly slash prices of obesity drugs, posing a direct financial challenge to revenue and earnings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1d ago
+23.9%
Price is moving against the score
$1145.00 vs $924.37 close before publication (Nov 7) · not market-adjusted
LLY chart →
